People_

Professor Peter Hersey

Professor of Melanoma Biology
Northern Clinical School
Faculty of Medicine and Health

Phone

+61 2 9926 4715/4737

peter.hersey@sydney.edu.au

Professor Hersey is a graduate in medicine from the University of Adelaide and in science from the University of Oxford where he completed a D.Phil in tumor immunology. He has worked closely with the Sydney and Newcastle Melanoma Units on Immunological aspects of melanoma and has been the principal investigator for a randomized trial of adjuvant immunotherapy in Stage 11b,111 melanoma and several trials of dendritic cell vaccines in patients with stage IV melanoma. He is Professor of Melanoma Biology at the University of Sydney, Research Director of the Newcastle Melanoma Unit and Consultant Immunologist to the Melanoma Institute Australia. He is a Member of the International working group on Melanoma and the Global melanoma task force. He has contributed extensively to studies on sensitivity of melanoma cells to apoptosis induced by the immune system and chemotherapy and treatments which sensitize melanoma to therapy. He holds the view that overcoming resistance to cell death pathways in melanoma holds the key to advances in treatment of melanoma. He is joint holder of a National Health and Medical Research Council Program grant for studies on melanoma. He is on the editorial board of a number of international journals and has contributed extensively to melanoma research. Dr Hersey is author of over 260 papers on original research related to melanoma.

Themes

Cancer

Keywords

Melanoma and skin cancer

Clinical speciality

Surgery

Publications

By Type

Expand all

Book Chapters

Hersey, P., Gallagher, S., Mijatov, B. (2013). Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors. In B. Bonavida (Eds.), Resistance to Immunotherapeutic Antibodies in Cancer: Resistance to Targeted Anti-Cancer Therapeutics, Vol 2, (pp. 143-155). United States: Springer Science+Business Media. [More Information]
Hersey, P., Zhang, X. (2012). Targeting Apoptotic Pathways in Melanoma. In T F Gajewski, F S Hodi (Eds.), Targeted Therapeutics in Melanoma, (pp. 125-154). New York: Humana Press. [More Information]
Zhang, X., Hersey, P., Tay, K., Tseng, H., Jiang, C., Dong, L. (2011). Adaptation to ER Stress as a Mechanism of Resistance of Melanoma to Treatment. In Ming Yu Cao (Eds.), Current Management of Malignant Melanoma, (pp. 253-274). Rijeka, Croatia: InTech Publishers. [More Information]

Journals

Tseng, H., Alavi, S., Gallagher, S., McGuire, H., Hersey, P., Emran, A., Tiffen, J. (2024). BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment. Pigment Cell & Melanoma Research. [More Information]
Alavi, S., Emran, A., Tseng, H., Tiffen, J., McGuire, H., Hersey, P. (2022). Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells. Cancers, 14(2), 323. [More Information]
Ahmed, F., Tseng, H., Ahn, A., Gunatilake, D., Alavi, S., Eccles, M., Rizos, H., Gallagher, S., Tiffen, J., Hersey, P., Emran, A. (2022). Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. Journal of Investigative Dermatology, 142(5), 1444-1.46E+13. [More Information]
Emran, A., Tseng, H., Gunatilake, D., Cook, S., Ahmed, F., Wang, S., Hersey, P., Gallagher, S., Tiffen, J. (2021). A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. Journal of Investigative Dermatology, 141(9), 2238-2249. [More Information]
Hamid, O., Robert, C., Daud, A., Carlino, M., Mitchell, T., Hersey, P., Schachter, J., Long, G., Hodi, F., Wolchok, J., Joshua, A., et al (2021). Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 157, 391-402. [More Information]
Robert, C., Hwu, W., Hamid, O., Ribas, A., Weber, J., Daud, A., Hodi, F., Wolchok, J., Mitchell, T., Hersey, P., Long, G., Carlino, M., Joshua, A., et al (2021). Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 144, 182-191. [More Information]
Punnia-Moorthy, G., Hersey, P., Emran, A., Tiffen, J. (2021). Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers. Frontiers in Genetics, 12, 680633. [More Information]
Emran, A., Gallagher, S., Tiffen, J., Hersey, P. (2021). Sex bias of females in survival from cancer and infections. Is X the answer? British Journal of Cancer, 124(7), 1184-1186. [More Information]
Ahn, A., Rodger, E., Motwani, J., Gimenez, G., Stockwell, P., Parry, M., Hersey, P., Chatterjee, A., Eccles, M. (2021). Transcriptional reprogramming and constitutive pd-l1 expression in melanoma are associated with dedifferentiation and activation of interferon and tumour necrosis factor signalling pathways. Cancers, 13(17), 4250. [More Information]
Dizier, B., Callegaro, A., Debois, M., Dreno, B., Hersey, P., Gogas, H., Kirkwood, J., Vansteenkiste, J., Sequist, L., Atanackovic, D., et al (2020). A Th1/IFNG gene signature is prognostic in the adjuvant setting of resectable high-risk melanoma but not in non-small cell lung cancer. Clinical Cancer Research, 26(7), 1725-1735. [More Information]
Tseng, H., Dreyer, J., Emran, A., Gunatilake, D., Pirozyan, M., Cullinane, C., Dutton-Regester, K., Rizos, H., Hayward, N., McArthur, G., Hersey, P., Tiffen, J., Gallagher, S. (2020). Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma. International Journal of Cancer, 147(8), 2176-2189. [More Information]
Emran, A., Tseng, H., Coleman, M., Tiffen, J., Cook, S., McGuire, H., Gallagher, S., Feng, C., Hersey, P. (2020). Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma? Pigment Cell & Melanoma Research, 33(5), 660-670. [More Information]
Rowdo, F., Barón, A., Gallagher, S., Hersey, P., Emran, A., von Euw, E., Barrio, M., Mordoh, J. (2020). Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition. International Journal of Oncology, 56(6), 1429-1441. [More Information]
Tiffen, J., Gallagher, S., Filipp, F., Gunatilake, D., Emran, A., Cullinane, C., Dutton-Register, K., Aoude, L., Hayward, N., Chatterjee, A., Hersey, P., et al (2020). EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. Journal of Investigative Dermatology, 140(12), 2442-2454. [More Information]
Owen, C., Shoushtari, A., Chauhan, D., Palmieri, D., Lee, B., Rohaan, M., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hersey, P., Lo, S., Carlino, M., Menzies, A., Long, G., et al (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Annals of Oncology, 31(8), 1075-1082. [More Information]
Pirozyan, M., McGuire, H., Emran, A., Tseng, H., Tiffen, J., Lee, J., Carlino, M., Menzies, A., Long, G., Scolyer, R., Fazekas de St Groth, B., Hersey, P. (2020). Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Frontiers in Immunology, 11, 372. [More Information]
Bailey, M., Meyerson, W., Dursi, L., Wang, L., Dong, G., Liang, W., Weerasinghe, A., Li, S., Burke, H., Chiew, Y., Chou, A., Dagg, R., De Paoli-Iseppi, R., Gill, A., Hayward, N., Hersey, P., Jakrot, V., Kakavand, H., Kench, J., Kennedy, C., Mann, G., Pupo, G., Samra, J., Schramm, S., Scolyer, R., Tembe, V., Vilain, R., Yang, J., deFazio, A., et al (2020). Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 11(1), 1-27. [More Information]
Li, C., Prokopec, S., Sun, R., Yousif, F., Schmitz, N., Al-Shahrour, F., Atwal, G., Bailey, P., Biankin, A., Burke, H., et al (2020). Sex differences in oncogenic mutational processes. Nature Communications, 11(1), 4330. [More Information]
Emran, A., Nsengimana, J., Punnia-Moorthy, G., Schmitz, U., Gallagher, S., Newton-Bishop, J., Tiffen, J., Hersey, P. (2020). Study of the female sex survival advantage in melanoma—a focus on x-linked epigenetic regulators and immune responses in two cohorts. Cancers, 12(8), 1-21. [More Information]
Robert, C., Flaherty, M., Nathan, P., Hersey, P., Garbe, C., Milhem, M., Demidov, L., Mohr, P., Hassel, J., Rutkowski, P., et al (2019). Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma. European Journal of Cancer, 109, 61-69. [More Information]
Hamid, O., Robert, C., Daud, A., Hodi, F., Hwu, W., Kefford, R., Wolchok, J., Hersey, P., Joseph, R., Weber, J., Joshua, A., et al (2019). Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of Oncology, 30(4), 582-588. [More Information]
Hersey, P., Tiffen, J., Gallagher, S. (2019). Shedding light on dabrafenib-induced fevers in patients with melanoma. The Lancet Oncology, 20(12), 1637-1638. [More Information]
Emran, A., Chatterjee, A., Rodger, E., Tiffen, J., Gallagher, S., Eccles, M., Hersey, P. (2019). Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. Trends in Immunology, 40(4), 328-344. [More Information]
McGuire, H., Shklovskaya, E., Edwards, J., Trevillian, P., McCaughan, G., Bertolino, P., McKenzie, C., Gourlay, R., Gallagher, S., Fazekas de St Groth, B., Hersey, P. (2018). Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunology, Immunotherapy, 67(4), 563-573. [More Information]
Joseph, R., Elassaiss-Schaap, J., Kefford, R., Hwu, W., Wolchok, J., Joshua, A., Ribas, A., Hodi, F., Hamid, O., Robert, C., Hersey, P., et al (2018). Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clinical Cancer Research, 24(20), 4960-4967. [More Information]
Edwards, J., Wilmott, J., Madore, J., Gide, T., Quek, C., Tasker, A., Ferguson, A., Chen, J., Hewavisenti, R., Hersey, P., Weninger, W., Britton, W., Saw, R., Thompson, J., Menzies, A., Long, G., Scolyer, R., Palendira, M., et al (2018). CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. Clinical Cancer Research, 24(13), 3036-3045. [More Information]
Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J., Joshua, A., Hwu, W., Weber, J., Gangadhar, T., Joseph, R., Hersey, P., et al (2018). Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. Journal of Clinical Oncology, 36(17), 1668-1674. [More Information]
Gallagher, S., Gunatilake, D., Beaumont, K., Sharp, D., Tiffen, J., Heinemann, A., Weninger, W., Haass, N., Wilmott, J., Madore, J., Ferguson, P., Rizos, H., Hersey, P. (2018). HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. International Journal of Cancer, 142(9), 1926-1937. [More Information]
Dreno, B., Thompson, J., Smithers, B., Santinami, M., Jouary, T., Gutzmer, R., Levchenko, E., Rutkowski, P., Grob, J., Korovin, S., Hersey, P., et al (2018). MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 19(7), 916-929. [More Information]
Chatterjee, D., Rodger, E., Ahn, A., Stockwell, P., Parry, M., Motwani, J., Gallagher, S., Shklovskaya, E., Tiffen, J., Eccles, M., Hersey, P. (2018). Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma. iScience, 4, 312-325. [More Information]
Strub, T., Ghiraldini, F., Carcamo, S., Li, M., Wroblewska, A., Singh, R., Goldberg, M., Hasson, D., Wang, Z., Gallagher, S., Hersey, P., Long, G., Scolyer, R., Zheng, B., et al (2018). SIRT6 haploinsufficiency induces BRAF^V600E melanoma cell resistance to MAPK inhibitors via IGF signalling. Nature Communications, 9(1). [More Information]
Faries, M., Thompson, J., Cochran, A., Andtbacka, R., Mozzillo, N., Zager, J., Jahkola, T., Bowles, T., Testori, A., Beitsch, P., Nieweg, O., et al (2017). Completion dissection or observation for sentinel-node metastasis in melanoma. New England Journal of Medicine, 376(23), 2211-2222. [More Information]
Hersey, P., McAleer, S. (2017). Developing an e-learning resource for nurse airway assistants in the emergency department. British Journal of Nursing, 26(4), 217-221. [More Information]
Gallagher, S., Shklovskaya, E., Hersey, P. (2017). Epigenetic modulation in cancer immunotherapy. Current Opinion in Pharmacology, 35, 48-56. [More Information]
Lomax, A., McGuire, H., McNeil, C., Choi, C., Hersey, P., Karikios, D., Shannon, K., Van Hal, S., Carr, U., Crotty, A., Hollingsworth, J., Kim, H., Fazekas de St Groth, B., McGill, N., et al (2017). Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis. International Journal of Rheumatic Diseases, 20(9), 1277-1285. [More Information]
Hayward, N., Wilmott, J., Waddell, N., Johansson, P., Field, M., Nones, K., Patch, A., Kakavand, H., Alexandrov, L., Burke, H., Jakrot, V., Tembe, V., Pupo, G., De Paoli-Iseppi, R., Vilain, R., Shang, P., Lau, L., Dagg, R., Schramm, S., Pickett, H., Yang, J., Stretch, J., Kefford, R., Hersey, P., Long, G., Spillane, A., Saw, R., Thompson, J., Scolyer, R., Mann, G., et al (2017). Whole-genome landscapes of major melanoma subtypes. Nature, 545(7653), 175-180. [More Information]
Pulvirenti, T., Hong, A., Clements, A., Forstner, D., Suchowersky, A., Guminski, A., McNeil, C., Hersey, P., Fogarty, G., Kefford, R., Long, G., Wang, T. (2016). Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. Journal of Clinical Oncology, 34(3), e17-e20. [More Information]
Ribas, A., Hamid, O., Daud, A., Hodi, F., Wolchok, J., Kefford, R., Joshua, A., Patnaik, A., Hwu, W., Hersey, P., et al (2016). Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA - Journal of the American Medical Association, 315(15), 1600-1609. [More Information]
Hodi, F., Hwu, W., Kefford, R., Weber, J., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Hersey, P., et al (2016). Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab. Journal of Clinical Oncology, 34(13), 1510-1517. [More Information]
Tiffen, J., Gallagher, S., Tseng, H., Filipp, F., Fazekas de St Groth, B., Hersey, P. (2016). EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell & Melanoma Research, 29(5), 500-507. [More Information]
Daud, A., Wolchok, J., Robert, C., Hwu, W., Weber, J., Ribas, A., Hodi, F., Joshua, A., Kefford, R., Hersey, P., et al (2016). Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. Journal of Clinical Oncology, 34(34), 4102-4109. [More Information]
Tiffen, J., Wilson, S., Gallagher, S., Hersey, P., Filipp, F. (2016). Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma. NeoPlasia: an international journal of oncology research, 18(2), 121-132. [More Information]
Heinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J., Gunatilake, D., Madore, J., Strbenac, D., Yang, J., Gowrishankar, K., Tiffen, J., Hersey, P., Gallagher, S., et al (2015). Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget, 6(25), 21507-21521. [More Information]
Wilmott, J., Colebatch, A., Kakavand, H., Shang, P., Carlino, M., Thompson, J., Long, G., Scolyer, R., Hersey, P. (2015). Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 28(7), 884-894. [More Information]
Tiffen, J., Gallagher, S., Hersey, P. (2015). EZH2: An emerging role in melanoma biology and strategies for targeted therapy. Pigment Cell & Melanoma Research, 28(1), 21-30. [More Information]
Gallagher, S., Tiffen, J., Hersey, P. (2015). Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Cancers, 7(4), 1959-1982. [More Information]
Gowrishankar, K., Gunatilake, D., Gallagher, S., Tiffen, J., Rizos, H., Hersey, P. (2015). Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. PloS One, 10(4), 1-19. [More Information]
Wainstein, A., Algarra, S., Bastholt, L., Cinat, G., Demidov, L., Grob, J., Guo, J., Hersey, P., Espinosa, E., Schachter, J., et al (2015). Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries. American Journal of Therapeutics (Online), 22(1), 37-43. [More Information]
Kakavand, H., Wilmott, J., Menzies, A., Vilain, R., Haydu, L., Yearley, J., Thompson, J., Kefford, R., Hersey, P., Long, G., Scolyer, R. (2015). PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clinical Cancer Research, 21(14), 3140-3148. [More Information]
Madore, J., Vilain, R., Menzies, A., Kakavand, H., Wilmott, J., Hyman, J., Yearley, J., Kefford, R., Thompson, J., Long, G., Hersey, P., Scolyer, R. (2015). PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell & Melanoma Research, 28(3), 245-253. [More Information]
Hersey, P., Gowrishankar, K. (2015). Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Future Oncology, 11(1), 133-140. [More Information]
Ascierto, P., Bastholt, L., Hersey, P., Cinat, G., Eggermont, A., Hauschild, A., Espinosa, E., Robert, C. (2015). Side effects and toxicities of targeted therapies in stage IV melanoma. American Journal of Therapeutics (Online), 22(1), 44-53. [More Information]
Wilmott, J., Hersey, P., Long, G., Scolyer, R. (2015). Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? Melanoma Management, 19(3), 269-272. [More Information]
Tiffen, J., Gunatilake, D., Gallagher, S., Gowrishankar, K., Heinemann, A., Cullinane, C., Dutton-Regester, K., Pupo, G., Strbenac, D., Yang, J., Madore, J., Mann, G., Hersey, P., et al (2015). Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget, 6(29), 27023-27036. [More Information]
Kakavand, H., Vilain, R., Wilmott, J., Burke, H., Yearley, J., Thompson, J., Hersey, P., Long, G., Scolyer, R. (2015). Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 28(12), 1535-1544. [More Information]
Hersey, P. (2014). Community experience of vemurafenib for BRAFV600 melanoma. The Lancet Oncology, 15(4), 369-370. [More Information]
Gallagher, S., Mijatov, B., Gunatilake, D., Gowrishankar, K., Tiffen, J., James, W., Jin, L., Pupo, G., Cullinane, C., McArthur, G., Rizos, H., Hersey, P., et al (2014). Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Pigment Cell & Melanoma Research, 27(6), 1126-1137. [More Information]
Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. Journal of Immunology, 192(5), 2505-2513. [More Information]
Hersey, P., Kakavand, H., Wilmott, J., van der Westhuizen, A., Gallagher, S., Gowrishankar, K., Scolyer, R. (2014). How Anti PD1 Treatments are Changing the Management Of Melanoma. Melanoma Management, 1(2), 165-172. [More Information]
Hersey, P., Gallagher, S. (2014). Intralesional immunotherapy for melanoma. Journal of Surgical Oncology, 109(4), 320-326. [More Information]
Oliveira, C., de Bock, C., Molloy, T., Sadeqzadeh, E., Geng, X., Hersey, P., Zhang, X., Thorne, R. (2014). Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma. BMC Cancer, 14, 1-14. [More Information]
Croft, A., Tay, K., Boyd, S., Guo, S., Jiang, C., Lai, F., Tseng, H., Jin, L., Rizos, H., Hersey, P., et al (2014). Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress. Journal of Investigative Dermatology, 134(2), 488-497. [More Information]
Coventry, B., Lilly, C., Hersey, P., Michele, A., Bright, R. (2014). Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma. Journal for ImmunoTherapy of Cancer, 2(1), 1-7. [More Information]
Jiang, C., Croft, A., Tseng, H., Guo, S., Jin, L., Hersey, P., Zhang, X. (2014). Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. Oncogene, 33(20), 2577-2588. [More Information]
Gallagher, S., Mijatov, B., Gunatilake, D., Tiffen, J., Gowrishankar, K., Jin, L., Pupo, G., Cullinane, C., Prinjha, R., Smithers, N., Rizos, H., Hersey, P., et al (2014). The Epigenetic Regulator I-BET151 Induces BIM Dependent Apoptosis and Cell Cycle Arrest OF Human Melanoma Cells. Journal of Investigative Dermatology, 134(11), 2795-2805. [More Information]
Hersey, P., Gallagher, S. (2013). A Focus on PD-L1 in Human Melanoma. Clinical Cancer Research, 19(3), 514-516. [More Information]
Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
Lai, F., Guo, S., Jin, L., Jiang, C., Wang, C., Croft, A., Chi, M., Tseng, H., Farelly, M., Atmadibrata, B., Hersey, P., et al (2013). Cotargeting histone deactylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death and Disease, 4, 1-13. [More Information]
Wroblewski, D., Jiang, C., Croft, A., Farrelly, M., Zhang, X., Hersey, P. (2013). OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. PloS One, 8(12), 1-13. [More Information]
Trunzer, K., Pavlick, A., Schuchter, L., Gonzalez, R., McArthur, G., Hutson, T., Moschos, S., Flaherty, K., Kim, K., Weber, J., Hersey, P., Long, G., et al (2013). Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 31(14), 1767-1774. [More Information]
Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4, 1-15. [More Information]
Bowden, N., Ashton, K., Vilain, R., Avery-Kiejda, K., Davey, R., Murray, H., Budden, T., Braye, S., Zhang, X., Hersey, P., et al (2013). Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma. PloS One, 8(8), 1-8. [More Information]
Hamid, O., Robert, C., Daud, A., Hodi, F., Hwu, W., Kefford, R., Wolchok, J., Hersey, P., Joseph, R., Weber, J., et al (2013). Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. New England Journal of Medicine, 369(2), 134-144. [More Information]
Wroblewski, D., Mijatov, B., Mohana-Kumara, N., Lai, F., Gallagher, S., Haass, N., Zhang, X., Hersey, P. (2013). The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 34(2), 237-247. [More Information]
Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
Lai, F., Jiang, C., Farrelly, M., Zhang, X., Hersey, P. (2012). Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Melanoma Research, 22(3), 244-251. [More Information]
Lai, F., Jin, L., Gallagher, S., Mijatov, B., Zhang, X., Hersey, P. (2012). Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors. Advances in Pharmacology, 65, 27-43. [More Information]
Flaherty, K., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L., Hassel, J., Rutkowski, P., Mohr, P., et al (2012). Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 367(2), 107-114. [More Information]
Shayan, R., Karnezis, T., Murali, R., Wilmott, J., Ashton, M., Taylor, G., Thompson, J., Hersey, P., Achen, M., Scolyer, R., et al (2012). Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 61(4), 702-710. [More Information]
Lucas, K., Kumaran - Mohana, N., Lau, D., Zhang, X., Hersey, P., Huang, D., Weninger, W., Haass, N., Allen, J. (2012). Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737. Clinical Cancer Research, 18(3), 783-795. [More Information]
Ribas, A., Hersey, P., Middleton, M., Gogas, H., Flaherty, K., Sondak, V., Kirkwood, J. (2012). New challenges in endpoints for drug development in advanced melanoma. Clinical Cancer Research, 18(2), 336-341. [More Information]
Kirkwood, J., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., et al (2012). Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical Cancer Research, 18(2), 555-567. [More Information]
Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
Tay, K., Jin, L., Tseng, H., Jiang, C., Ye, Y., Thorne, R., Liu, T., Guo, S., Verrills, N., Hersey, P., et al (2012). Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. Cell Death and Disease, 3, 1-11. [More Information]
Sosman, J., Kim, K., Schuchter, L., Gonzalez, R., Pavlick, A., Weber, J., McArthur, G., Hutson, T., Moschos, S., Flaherty, K., Hersey, P., Kefford, R., et al (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New England Journal of Medicine, 366(8), 707-714. [More Information]
Tseng, H., Chen, L., Ye, Y., Tay, K., Jiang, C., Guo, S., Jin, L., Hersey, P., Zhang, X. (2012). The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells. Carcinogenesis, 33(10), 1871-1881. [More Information]
Sadeqzadeh, E., de Bock, C., Zhang, X., Shipman, K., Scott, N., Song, C., Yeadon, T., Oliveira, C., Jin, B., Hersey, P., et al (2011). Dual Processing of FAT1 Cadherin Protein by Human Melanoma Cells Generates Distinct Protein Products. Journal of Biological Chemistry, 286(32), 28181-28191. [More Information]
Dong, L., Jiang, C., Thorne, R., Croft, A., Yang, F., Liu, H., de Bock, C., Hersey, P., Zhang, X. (2011). Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene, 30(34), 3716-3726. [More Information]
Hersey, P., Smalley, K., Weeraratna, A., Bosenberg, M., Zhang, X., Haass, N., Paton, E., Mann, G., Scolyer, R. (2011). Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell & Melanoma Research, 24(1), e1-e15. [More Information]
Jiang, C., Lai, F., Thorne, R., Yang, F., Liu, H., Hersey, P., Zhang, X. (2011). MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clinical Cancer Research, 17(4), 721-730. [More Information]
Jin, L., Hu, W., Jiang, C., Wang, J., Han, C., Chu, P., Zhang, L., Thorne, R., Wilmott, J., Scolyer, R., Hersey, P., et al (2011). MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 108(38), 15840-15845. [More Information]
Avery-Kiejda, K., Bowden, N., Croft, A., Scurr, L., Kairupan, C., Ashton, K., Talseth-Palmer, B., Rizos, H., Zhang, X., Scott, R., et al (2011). P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer, 11(203), 1-17. [More Information]
Wilmott, J., Zhang, X., Hersey, P., Scolyer, R. (2011). The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 43(6), 657-671. [More Information]
Zalaudek, I., Whiteman, D., Rosendahl, C., Menzies, S., Green, A., Hersey, P., Argenziano, G. (2011). Update on melanoma and non-melanoma skin cancer. Expert Review of Anticancer Therapy, 11(12), 1829-1832. [More Information]
Hersey, P., Sosman, J., O'Day, S., Richards, J., Bedikian, A., Gonzalez, R., Sharfman, W., Weber, R., Logan, T., Buzoianu, M., et al (2010). A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer, 116(6), 1526-1534. [More Information]
Kefford, R., Clingan, P., Brady, B., Ballmer, A., Morganti, A., Hersey, P. (2010). A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Molecular Cancer, 9(69), 69-1-69-9. [More Information]
Jiang, C., Lai, F., Tay, K., Croft, A., Rizos, H., Becker, T., Yang, F., Liu, H., Thorne, R., Hersey, P., et al (2010). Apoptosis of Human Melanoma Cells Induced by Inhibition of B-RAFV600E Involves Preferential Splicing of BimS. Cell Death and Disease, 1(9), e69-1-e69-14. [More Information]
Fonsatti, E., Maio, M., Altomonte, M., Hersey, P. (2010). Biology and clinical applications of CD40 in cancer treatment. Seminars in Oncology, 37(5), 517-523. [More Information]
Tseng, H., Jiang, C., Croft, A., Tay, K., Thorne, R., Yang, F., Liu, H., Hersey, P., Zhang, X. (2010). Contrasting Effects of Nutlin-3 on TRAIL- and Docetaxel-Induced Apoptosis Due to Upregulation of TRAIL-R2 and Mcl-1 in Human Melanoma Cells. Molecular Cancer Therapeutics, 9(12), 3363-3374. [More Information]
Yang, F., Tay, K., Dong, L., Thorne, R., Jiang, C., Yang, E., Tseng, H., Liu, H., Christopherson, R., Hersey, P., et al (2010). Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death and Differentiation, 17(8), 1354-1367. [More Information]
Hersey, P. (2010). Immunotherapy of melanoma. Asia-Pacific Journal of Clinical Oncology, 6(Suppl 1), S2-S8. [More Information]
Zhuang, L., Scolyer, R., Murali, R., McCarthy, S., Zhang, X., Thompson, J., Hersey, P. (2010). Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Modern Pathology, 23(1), 45-53. [More Information]
Bowden, N., Ashton, K., Avery-Kiejda, K., Zhang, X., Hersey, P., Scott, R. (2010). Nucleotide excision repair gene expression after Cisplatin treatment in melanoma. Cancer Research, 70(20), 7918-7926. [More Information]
Kirkwood, J., Lorigan, P., Hersey, P., Hauschild, A., Robert, C., McDermott, D., Marshall, M., Gomez-Navarro, J., Liang, J., Bulanhagui, C. (2010). Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clinical Cancer Research, 16(3), 1042-0432. [More Information]
Eisen, T., Trefzer, U., Hamilton, A., Hersey, P., Millward, M., Knight, R., Jungnelius, J., Glaspy, J. (2010). Results of a Multicenter, Randomized, Double-Blind Phase 2/3 Study of Lenalidomide in the Treatment of Pretreated Relapsed or Refractory Metastatic Malignant Melanoma. Cancer, 116(1), 146-154. [More Information]
Mao, Z., Jiang, C., Yang, F., Thorne, R., Hersey, P., Zhang, X. (2010). TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4. Apoptosis, 15(10), 1211-1222. [More Information]
Liu, H., Jiang, C., Lavis, C., Croft, A., Dong, L., Tseng, H., Yang, F., Tay, K., Hersey, P., Zhang, X. (2009). 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Molecular Cancer, 8, 1-17. [More Information]
Gogas, H., Eggermont, A., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., Dummer, R. (2009). Biomarkers in melanoma. Annals of Oncology, 20(SUPP 6), vi8-vi13. [More Information]
Zhuang, L., Scolyer, R., Lee, C., McCarthy, S., Cooper, W., Zhang, X., Thompson, J., Hersey, P. (2009). Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. Histopathology, 54(4), 462-470. [More Information]
Jiang, C., Mao, Z., Avery-Kiejda, K., Wade, M., Hersey, P., Zhang, X. (2009). Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis, 30(2), 197-204. [More Information]
Jiang, C., Yang, F., Thorne, R., Zhu, B., Hersey, P., Zhang, X. (2009). Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. NeoPlasia: an international journal of oncology research, 11(5), 436-447. [More Information]
Jiang, C., Wroblewski, D., Yang, F., Hersey, P., Zhang, X. (2009). Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. NeoPlasia: an international journal of oncology research, 11(9), 945-955. [More Information]
Schadendorf, D., Algarra, S., Bastholt, L., Cinat, G., Dreno, B., Eggermont, A., Espinosa, E., Guo, J., Hauschild, A., Petrella, T., Hersey, P., et al (2009). Immunotherapy of distant metastatic disease. Annals of Oncology, 20(6), vi41-vi50. [More Information]
Zhang, L., Chen, S., Wu, P., Hu, C., Thorne, R., Luo, C., Hersey, P., Zhang, X. (2009). Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells. Cancer Letters, 274(1), 40-46. [More Information]
Hersey, P., Watts, R., Zhang, X., Hackett, J. (2009). Metabolic approaches to treatment of melanoma. Clinical Cancer Research, 15(21), 6490-6494. [More Information]
Watson, A., Middleton, M., McGown, G., Thorncraft, M., Ranson, M., Hersey, P., McArthur, G., Davis, I., Thomson, D., Beith, J., Kefford, R., et al (2009). O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. British Journal of Cancer, 100(8), 1250-1256. [More Information]
Hauschild, A., Agarwala, S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., et al (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. Journal of Clinical Oncology, 27(17), 2823-2830. [More Information]
Hersey, P., Bastholt, L., Chiarion-Sileni, V., Cinat, G., Dummer, R., Eggermont, A., Espinosa, E., Hauschild, A., Quirt, I., Robert, C., et al (2009). Small molecules and targeted therapies in distant metastatic disease. Annals of Oncology, 20(6), vi35-40. [More Information]
Beusterien, K., Szabo, S., Kotapati, S., Mukherjee, J., Hoos, A., Hersey, P., Middleton, M., Levy, A. (2009). Societal preference values for advanced melanoma health states in the United Kingdom and Australia. British Journal of Cancer, 101(3), 387-389. [More Information]
Hersey, P., Zhang, X. (2009). Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. Cancer Immunology, Immunotherapy, 58(11), 1749-1759. [More Information]
Eggermont, A., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., Gogas, H., MacKie, R., Hauschild, A. (2009). Utility of adjuvant systemic therapy in melanoma. Annals of Oncology, 20(SUPP 6), vi30-vi34. [More Information]
Zhu, B., Wang, P., Zhang, X., Jiang, C., Chen, L., Avery-Kiejda, K., Watts, R., Hersey, P. (2008). Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells. Anti-Cancer Drugs, 19(2), 189-200. [More Information]
Hersey, P., Zhang, X. (2008). Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell & Melanoma Research, 21(3), 358-367. [More Information]
Thompson, J., Hersey, P., Wachter, E. (2008). Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Research, 18, 405-411. [More Information]
Zhang, L., Hao, Y., Hu, C., Ye, Y., Xie, Q., Thorne, R., Hersey, P., Zhang, X. (2008). Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells. Anti-Cancer Drugs, 19(2), 159-166. [More Information]
Chen, L., Jiang, C., Watts, R., Thorne, R., Avery-Kiejda, K., Zhang, X., Hersey, P. (2008). Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein. Cancer Research, 68(3), 834-842. [More Information]
Mhaidat, N., Thorne, R., Zhang, X., Hersey, P. (2008). Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma. Apoptosis, 13(12), 1505-1512. [More Information]
Mhaidat, N., Thorne, R., de Bock, C., Zhang, X., Hersey, P. (2008). Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels. FEBS Letters, 582(2), 267-272. [More Information]
Hersey, P., Zhang, X., Mhaidat, N. (2008). Overcoming resistance to apoptosis in cancer therapy. Advances in Experimental Medicine and Biology, 615, 105-126. [More Information]
Hersey, P., Halliday, G., Farrelly, M., DeSilva, C., Menzies, S., Lett, M. (2008). Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunology, Immunotherapy, 57(7), 1039-1051. [More Information]
Avery-Kiejda, K., Zhang, X., Adams, L., Scott, R., Vojtesek, B., Lane, D., Hersey, P. (2008). Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clinical Cancer Research, 14(6), 1659-1668. [More Information]
Jiang, C., Lucas, K., Avery-Kiejda, K., Wade, M., deBock, C., Thorne, R., Allen, J., Hersey, P., Zhang, X. (2008). Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Research, 68(16), 6708-6717. [More Information]
Yu, F., Chen, C., Kiejda, K., Gillespie, S., Xu, D., Hersey, P. (2007). Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clinical Cancer Research, 13(16), 4934-4942. [More Information]
Mhaidat, N., Wang, Y., Kiejda, K., Zhang, X., Hersey, P. (2007). Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Molecular Cancer Therapeutics, 6(2), 752-761. [More Information]
Mhaidat, N., Zhang, X., Jaing, C., Hersey, P. (2007). Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clinical Cancer Research, 13(4), 1308-1314. [More Information]
Jiang, C., Chen, L., Gillespie, S., Wang, Y., Kiejda, K., Zhang, X., Hersey, P. (2007). Inhibition of MEK Sensitizes Human Melanoma Cells to Endoplasmic Reticulum Stress-Induced Apoptosis. Cancer Research, 67(20), 9750-9761. [More Information]
Zhuang, L., Lee, C., Scolyer, R., McCarthy, S., Hersey, P., Thompson, J., Zhang, X. (2007). Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology, 20(4), 416-426. [More Information]
Ranson, M., Hersey, P., Thompson, D., Beith, J., McArthur, G., Haydon, A., Davis, I., Kefford, R., Mortimer, P., Harris, P., et al (2007). Randomised trial of the combination of lomeguatrib and temozolomide and temozolomide alone in chemotherapy-naÃ¯ve patients with metastatic cutaneous melanoma. Journal of Clinical Oncology, 25(18), 2540-2545. [More Information]
Mhaidat, N., Thorne, R., Zhang, X., Hersey, P. (2007). Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Molecular Cancer Research, 5(10), 1073-1081. [More Information]
Mhaidat, N., Zhang, X., Allen, J., Avery-Kiejda, K., Scott, R., Hersey, P. (2007). Temozolomide induces senescence but not apoptosis in human melanoma cells. British Journal of Cancer, 97(9), 1225-1233. [More Information]
Chen, L., Jiang, C., Kiejda, K., Wang, Y., Thorne, R., Zhang, X., Hersey, P. (2007). Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response. Carcinogenesis, 28(11), 2328-2336. [More Information]
Chen, C., Li, H., Gillespie, S., Kiejda, K., Mhaidat, N., Yu, F., Thorne, R., Xu, D., Hersey, P. (2007). Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Research, 67(12), 5880-5888. [More Information]
Hersey, P. (2006). Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Current Opinion in Oncology, 18(2), 189-96. [More Information]
Bedikian, A., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A., DeConti, R., Hersh, E., Hersey, P., et al (2006). Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group. Journal of Clinical Oncology, 24(29), 4738-4745. [More Information]
Gillespie, S., Borrow, J., Zhang, X., Hersey, P. (2006). Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis, 11(12), 2251-2265. [More Information]
Zhang, X., Wu, J., Gillespie, S., Borrow, J., Hersey, P. (2006). Cross resistance of melanoma to trail-induced apoptosis and chemotherapy. Update on Cancer Therapeutics, 1(4), 435-441. [More Information]
Hersey, P., Zhuang, L., Zhang, X. (2006). Current Strategies in Overcoming Resistance of Cancer Cells to Apoptosis Melanoma as a Model. International Review of Cytology-a Survey of Cell Biology, 251, 131-158. [More Information]
Zhang, X., Wu, J., Gillespie, S., Borrow, J., Hersey, P. (2006). Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clinical Cancer Research, 12(4), 1355-1364. [More Information]
Hersey, P. (2006). Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells. Anti-Cancer Drugs, 17(10), 1151-61. [More Information]
Zhuang, L., Lee, C., Scolyer, R., McCarthy, S., Zhang, X., Thompson, J., Screaton, G., Hersey, P. (2006). Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Human Pathology, 37(10), 1286-1294. [More Information]
Zhuang, L., Lee, C., Scolyer, R., McCarthy, S., Palmer, A., Zhang, X., Thompson, J., Bron, L., Hersey, P. (2005). Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. Journal of Clinical Pathology, 58(11), 1163-1169. [More Information]
Millward, M., Joshua, A., Kefford, R., Aamdal, S., Thomson, D., Hersey, P., Toner, G., Lynch, K. (2005). Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Investigational New Drugs, 23(3), 253-256. [More Information]
Hersey, P., Menzies, S., Coventry, B., Nguyen, T., Farrelly, M., Collins, S., Hirst, D., Johnson, H. (2005). Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunology, Immunotherapy, 54(3), 208-218. [More Information]
Wu, J., Zhang, X., Gillespie, S., Hersey, P. (2005). Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Letters, 579(9), 1940-1944. [More Information]
Byrne, C., Thompson, J., Johnston, H., Hersey, P., Quinn, M., Hughes, M., McCarthy, W. (2005). Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Research, 15(1), 45-51. [More Information]
Gillespie, S., Zhang, X., Hersey, P. (2005). Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Molecular Cancer Therapeutics, 4(4), 668-76. [More Information]
Bron, L., Scolyer, R., Thompson, J., Hersey, P. (2004). Histological Expression Of Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) In Human Primary Melanoma. Pathology, 36(6), 561-565. [More Information]
Hersey, P., Menzies, S., Halliday, G., Nguyen, T., Farrelly, M., De Silva, C., Lett, M. (2004). Phase I/II Study Of Treatment With Dendritic Cell Vaccines In Patients With Disseminated Melanoma. Cancer Immunology, Immunotherapy, 53(2), 125-134. [More Information]
Ishri, R., Menzies, S., Hersey, P., Halliday, G. (2004). Rapid Downregulation Of Antigen Processing Enzymes In Ex Vivo Generated Human Monocyte Derived Dendritic Cells Occur Endogenously In Extended Cultures. Immunology and Cell Biology, 82(3), 239-246. [More Information]
Thompson, J., Shaw, H., Hersey, P., Scolyer, R. (2004). The History And Future Of Melanoma Staging. Journal of Surgical Oncology, 86(4), 224-235. [More Information]
Hanrahan, P., D'Este, C., Menzies, S., Plummer, T., Hersey, P. (2002). A randomised trial of skin photography as an aid to screening skin lesions in older males. Journal of Medical Screening, 9(3), 128-132. [More Information]
Coates, A., Thompson, J., McMullen, A., Simes, R., McCarthy, W., Hersey, P., Sillar, R., Mcleod, R., Gill, P., Coventry, B., Dhillon, H. (2002). Adjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial. Journal of Clinical Oncology, 20(20), 4181-4189.
Saleh, F., Crotty, K., Menzies, S., Hersey, P. (2001). Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-a/mart-1. International Journal of Cancer, 94, 551-557. [More Information]

show 161 more

Conferences

Johnstone, D., Gomez Ravetti, M., Moscato, P., Hersey, P., Scott, R., Milward, E. (2009). Metabolic gene expression in advanced melanoma. ASMR NSW State Scientific Meeting, Sydney, NSW, Australia.
Milward, E., Johnstone, D., Gomez Ravetti, M., Berretta, R., Hersey, P., Scott, R., Moscato, P. (2009). The relationship between Parkinson's disease and melanoma - insights from microarray analysis of genome-wide gene expression changes in melanoma. ASMR National Scientific Conference, Hobart, TAS, Australia.

By Year

Expand all

2024

Tseng, H., Alavi, S., Gallagher, S., McGuire, H., Hersey, P., Emran, A., Tiffen, J. (2024). BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment. Pigment Cell & Melanoma Research. [More Information]

2022

Alavi, S., Emran, A., Tseng, H., Tiffen, J., McGuire, H., Hersey, P. (2022). Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells. Cancers, 14(2), 323. [More Information]
Ahmed, F., Tseng, H., Ahn, A., Gunatilake, D., Alavi, S., Eccles, M., Rizos, H., Gallagher, S., Tiffen, J., Hersey, P., Emran, A. (2022). Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. Journal of Investigative Dermatology, 142(5), 1444-1.46E+13. [More Information]

2021

Emran, A., Tseng, H., Gunatilake, D., Cook, S., Ahmed, F., Wang, S., Hersey, P., Gallagher, S., Tiffen, J. (2021). A Combination of Epigenetic BET and CDK9 Inhibitors for Treatment of Human Melanoma. Journal of Investigative Dermatology, 141(9), 2238-2249. [More Information]
Hamid, O., Robert, C., Daud, A., Carlino, M., Mitchell, T., Hersey, P., Schachter, J., Long, G., Hodi, F., Wolchok, J., Joshua, A., et al (2021). Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 157, 391-402. [More Information]
Robert, C., Hwu, W., Hamid, O., Ribas, A., Weber, J., Daud, A., Hodi, F., Wolchok, J., Mitchell, T., Hersey, P., Long, G., Carlino, M., Joshua, A., et al (2021). Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 144, 182-191. [More Information]
Punnia-Moorthy, G., Hersey, P., Emran, A., Tiffen, J. (2021). Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers. Frontiers in Genetics, 12, 680633. [More Information]
Emran, A., Gallagher, S., Tiffen, J., Hersey, P. (2021). Sex bias of females in survival from cancer and infections. Is X the answer? British Journal of Cancer, 124(7), 1184-1186. [More Information]
Ahn, A., Rodger, E., Motwani, J., Gimenez, G., Stockwell, P., Parry, M., Hersey, P., Chatterjee, A., Eccles, M. (2021). Transcriptional reprogramming and constitutive pd-l1 expression in melanoma are associated with dedifferentiation and activation of interferon and tumour necrosis factor signalling pathways. Cancers, 13(17), 4250. [More Information]

show 3 more

2020

Dizier, B., Callegaro, A., Debois, M., Dreno, B., Hersey, P., Gogas, H., Kirkwood, J., Vansteenkiste, J., Sequist, L., Atanackovic, D., et al (2020). A Th1/IFNG gene signature is prognostic in the adjuvant setting of resectable high-risk melanoma but not in non-small cell lung cancer. Clinical Cancer Research, 26(7), 1725-1735. [More Information]
Tseng, H., Dreyer, J., Emran, A., Gunatilake, D., Pirozyan, M., Cullinane, C., Dutton-Regester, K., Rizos, H., Hayward, N., McArthur, G., Hersey, P., Tiffen, J., Gallagher, S. (2020). Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma. International Journal of Cancer, 147(8), 2176-2189. [More Information]
Emran, A., Tseng, H., Coleman, M., Tiffen, J., Cook, S., McGuire, H., Gallagher, S., Feng, C., Hersey, P. (2020). Do innate killing mechanisms activated by inflammasomes have a role in treating melanoma? Pigment Cell & Melanoma Research, 33(5), 660-670. [More Information]
Rowdo, F., Barón, A., Gallagher, S., Hersey, P., Emran, A., von Euw, E., Barrio, M., Mordoh, J. (2020). Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long-term BRAF inhibition. International Journal of Oncology, 56(6), 1429-1441. [More Information]
Tiffen, J., Gallagher, S., Filipp, F., Gunatilake, D., Emran, A., Cullinane, C., Dutton-Register, K., Aoude, L., Hayward, N., Chatterjee, A., Hersey, P., et al (2020). EZH2 Cooperates with DNA Methylation to Downregulate Key Tumor Suppressors and IFN Gene Signatures in Melanoma. Journal of Investigative Dermatology, 140(12), 2442-2454. [More Information]
Owen, C., Shoushtari, A., Chauhan, D., Palmieri, D., Lee, B., Rohaan, M., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hersey, P., Lo, S., Carlino, M., Menzies, A., Long, G., et al (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Annals of Oncology, 31(8), 1075-1082. [More Information]
Pirozyan, M., McGuire, H., Emran, A., Tseng, H., Tiffen, J., Lee, J., Carlino, M., Menzies, A., Long, G., Scolyer, R., Fazekas de St Groth, B., Hersey, P. (2020). Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Frontiers in Immunology, 11, 372. [More Information]
Bailey, M., Meyerson, W., Dursi, L., Wang, L., Dong, G., Liang, W., Weerasinghe, A., Li, S., Burke, H., Chiew, Y., Chou, A., Dagg, R., De Paoli-Iseppi, R., Gill, A., Hayward, N., Hersey, P., Jakrot, V., Kakavand, H., Kench, J., Kennedy, C., Mann, G., Pupo, G., Samra, J., Schramm, S., Scolyer, R., Tembe, V., Vilain, R., Yang, J., deFazio, A., et al (2020). Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples. Nature Communications, 11(1), 1-27. [More Information]
Li, C., Prokopec, S., Sun, R., Yousif, F., Schmitz, N., Al-Shahrour, F., Atwal, G., Bailey, P., Biankin, A., Burke, H., et al (2020). Sex differences in oncogenic mutational processes. Nature Communications, 11(1), 4330. [More Information]
Emran, A., Nsengimana, J., Punnia-Moorthy, G., Schmitz, U., Gallagher, S., Newton-Bishop, J., Tiffen, J., Hersey, P. (2020). Study of the female sex survival advantage in melanoma—a focus on x-linked epigenetic regulators and immune responses in two cohorts. Cancers, 12(8), 1-21. [More Information]

show 7 more

2019

Robert, C., Flaherty, M., Nathan, P., Hersey, P., Garbe, C., Milhem, M., Demidov, L., Mohr, P., Hassel, J., Rutkowski, P., et al (2019). Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanoma. European Journal of Cancer, 109, 61-69. [More Information]
Hamid, O., Robert, C., Daud, A., Hodi, F., Hwu, W., Kefford, R., Wolchok, J., Hersey, P., Joseph, R., Weber, J., Joshua, A., et al (2019). Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Annals of Oncology, 30(4), 582-588. [More Information]
Hersey, P., Tiffen, J., Gallagher, S. (2019). Shedding light on dabrafenib-induced fevers in patients with melanoma. The Lancet Oncology, 20(12), 1637-1638. [More Information]
Emran, A., Chatterjee, A., Rodger, E., Tiffen, J., Gallagher, S., Eccles, M., Hersey, P. (2019). Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy. Trends in Immunology, 40(4), 328-344. [More Information]

show 1 more

2018

McGuire, H., Shklovskaya, E., Edwards, J., Trevillian, P., McCaughan, G., Bertolino, P., McKenzie, C., Gourlay, R., Gallagher, S., Fazekas de St Groth, B., Hersey, P. (2018). Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunology, Immunotherapy, 67(4), 563-573. [More Information]
Joseph, R., Elassaiss-Schaap, J., Kefford, R., Hwu, W., Wolchok, J., Joshua, A., Ribas, A., Hodi, F., Hamid, O., Robert, C., Hersey, P., et al (2018). Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clinical Cancer Research, 24(20), 4960-4967. [More Information]
Edwards, J., Wilmott, J., Madore, J., Gide, T., Quek, C., Tasker, A., Ferguson, A., Chen, J., Hewavisenti, R., Hersey, P., Weninger, W., Britton, W., Saw, R., Thompson, J., Menzies, A., Long, G., Scolyer, R., Palendira, M., et al (2018). CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naive Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. Clinical Cancer Research, 24(13), 3036-3045. [More Information]
Robert, C., Ribas, A., Hamid, O., Daud, A., Wolchok, J., Joshua, A., Hwu, W., Weber, J., Gangadhar, T., Joseph, R., Hersey, P., et al (2018). Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. Journal of Clinical Oncology, 36(17), 1668-1674. [More Information]
Gallagher, S., Gunatilake, D., Beaumont, K., Sharp, D., Tiffen, J., Heinemann, A., Weninger, W., Haass, N., Wilmott, J., Madore, J., Ferguson, P., Rizos, H., Hersey, P. (2018). HDAC inhibitors restore BRAF-inhibitor sensitivity by altering PI3K and survival signalling in a subset of melanoma. International Journal of Cancer, 142(9), 1926-1937. [More Information]
Dreno, B., Thompson, J., Smithers, B., Santinami, M., Jouary, T., Gutzmer, R., Levchenko, E., Rutkowski, P., Grob, J., Korovin, S., Hersey, P., et al (2018). MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Oncology, 19(7), 916-929. [More Information]
Chatterjee, D., Rodger, E., Ahn, A., Stockwell, P., Parry, M., Motwani, J., Gallagher, S., Shklovskaya, E., Tiffen, J., Eccles, M., Hersey, P. (2018). Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma. iScience, 4, 312-325. [More Information]
Strub, T., Ghiraldini, F., Carcamo, S., Li, M., Wroblewska, A., Singh, R., Goldberg, M., Hasson, D., Wang, Z., Gallagher, S., Hersey, P., Long, G., Scolyer, R., Zheng, B., et al (2018). SIRT6 haploinsufficiency induces BRAF^V600E melanoma cell resistance to MAPK inhibitors via IGF signalling. Nature Communications, 9(1). [More Information]

show 5 more

2017

Faries, M., Thompson, J., Cochran, A., Andtbacka, R., Mozzillo, N., Zager, J., Jahkola, T., Bowles, T., Testori, A., Beitsch, P., Nieweg, O., et al (2017). Completion dissection or observation for sentinel-node metastasis in melanoma. New England Journal of Medicine, 376(23), 2211-2222. [More Information]
Hersey, P., McAleer, S. (2017). Developing an e-learning resource for nurse airway assistants in the emergency department. British Journal of Nursing, 26(4), 217-221. [More Information]
Gallagher, S., Shklovskaya, E., Hersey, P. (2017). Epigenetic modulation in cancer immunotherapy. Current Opinion in Pharmacology, 35, 48-56. [More Information]
Lomax, A., McGuire, H., McNeil, C., Choi, C., Hersey, P., Karikios, D., Shannon, K., Van Hal, S., Carr, U., Crotty, A., Hollingsworth, J., Kim, H., Fazekas de St Groth, B., McGill, N., et al (2017). Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis. International Journal of Rheumatic Diseases, 20(9), 1277-1285. [More Information]
Hayward, N., Wilmott, J., Waddell, N., Johansson, P., Field, M., Nones, K., Patch, A., Kakavand, H., Alexandrov, L., Burke, H., Jakrot, V., Tembe, V., Pupo, G., De Paoli-Iseppi, R., Vilain, R., Shang, P., Lau, L., Dagg, R., Schramm, S., Pickett, H., Yang, J., Stretch, J., Kefford, R., Hersey, P., Long, G., Spillane, A., Saw, R., Thompson, J., Scolyer, R., Mann, G., et al (2017). Whole-genome landscapes of major melanoma subtypes. Nature, 545(7653), 175-180. [More Information]

show 2 more

2016

Pulvirenti, T., Hong, A., Clements, A., Forstner, D., Suchowersky, A., Guminski, A., McNeil, C., Hersey, P., Fogarty, G., Kefford, R., Long, G., Wang, T. (2016). Acute Radiation Skin Toxicity Associated With BRAF Inhibitors. Journal of Clinical Oncology, 34(3), e17-e20. [More Information]
Ribas, A., Hamid, O., Daud, A., Hodi, F., Wolchok, J., Kefford, R., Joshua, A., Patnaik, A., Hwu, W., Hersey, P., et al (2016). Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA - Journal of the American Medical Association, 315(15), 1600-1609. [More Information]
Hodi, F., Hwu, W., Kefford, R., Weber, J., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Hersey, P., et al (2016). Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with Pembrolizumab. Journal of Clinical Oncology, 34(13), 1510-1517. [More Information]
Tiffen, J., Gallagher, S., Tseng, H., Filipp, F., Fazekas de St Groth, B., Hersey, P. (2016). EZH2 as a mediator of treatment resistance in melanoma. Pigment Cell & Melanoma Research, 29(5), 500-507. [More Information]
Daud, A., Wolchok, J., Robert, C., Hwu, W., Weber, J., Ribas, A., Hodi, F., Joshua, A., Kefford, R., Hersey, P., et al (2016). Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. Journal of Clinical Oncology, 34(34), 4102-4109. [More Information]
Tiffen, J., Wilson, S., Gallagher, S., Hersey, P., Filipp, F. (2016). Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma. NeoPlasia: an international journal of oncology research, 18(2), 121-132. [More Information]

show 3 more

2015

Heinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J., Gunatilake, D., Madore, J., Strbenac, D., Yang, J., Gowrishankar, K., Tiffen, J., Hersey, P., Gallagher, S., et al (2015). Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget, 6(25), 21507-21521. [More Information]
Wilmott, J., Colebatch, A., Kakavand, H., Shang, P., Carlino, M., Thompson, J., Long, G., Scolyer, R., Hersey, P. (2015). Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 28(7), 884-894. [More Information]
Tiffen, J., Gallagher, S., Hersey, P. (2015). EZH2: An emerging role in melanoma biology and strategies for targeted therapy. Pigment Cell & Melanoma Research, 28(1), 21-30. [More Information]
Gallagher, S., Tiffen, J., Hersey, P. (2015). Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy. Cancers, 7(4), 1959-1982. [More Information]
Gowrishankar, K., Gunatilake, D., Gallagher, S., Tiffen, J., Rizos, H., Hersey, P. (2015). Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. PloS One, 10(4), 1-19. [More Information]
Wainstein, A., Algarra, S., Bastholt, L., Cinat, G., Demidov, L., Grob, J., Guo, J., Hersey, P., Espinosa, E., Schachter, J., et al (2015). Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries. American Journal of Therapeutics (Online), 22(1), 37-43. [More Information]
Kakavand, H., Wilmott, J., Menzies, A., Vilain, R., Haydu, L., Yearley, J., Thompson, J., Kefford, R., Hersey, P., Long, G., Scolyer, R. (2015). PD-L1 expression and tumor-infiltrating lymphocytes define different subsets of MAPK inhibitor treated melanoma patients. Clinical Cancer Research, 21(14), 3140-3148. [More Information]
Madore, J., Vilain, R., Menzies, A., Kakavand, H., Wilmott, J., Hyman, J., Yearley, J., Kefford, R., Thompson, J., Long, G., Hersey, P., Scolyer, R. (2015). PD-L1 expression in melanoma shows marked heterogeneity within and between patients: Implications for anti-PD-1/PD-L1 clinical trials. Pigment Cell & Melanoma Research, 28(3), 245-253. [More Information]
Hersey, P., Gowrishankar, K. (2015). Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. Future Oncology, 11(1), 133-140. [More Information]
Ascierto, P., Bastholt, L., Hersey, P., Cinat, G., Eggermont, A., Hauschild, A., Espinosa, E., Robert, C. (2015). Side effects and toxicities of targeted therapies in stage IV melanoma. American Journal of Therapeutics (Online), 22(1), 44-53. [More Information]
Wilmott, J., Hersey, P., Long, G., Scolyer, R. (2015). Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy? Melanoma Management, 19(3), 269-272. [More Information]
Tiffen, J., Gunatilake, D., Gallagher, S., Gowrishankar, K., Heinemann, A., Cullinane, C., Dutton-Regester, K., Pupo, G., Strbenac, D., Yang, J., Madore, J., Mann, G., Hersey, P., et al (2015). Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes. Oncotarget, 6(29), 27023-27036. [More Information]
Kakavand, H., Vilain, R., Wilmott, J., Burke, H., Yearley, J., Thompson, J., Hersey, P., Long, G., Scolyer, R. (2015). Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases. Modern Pathology, 28(12), 1535-1544. [More Information]

show 10 more

2014

Hersey, P. (2014). Community experience of vemurafenib for BRAFV600 melanoma. The Lancet Oncology, 15(4), 369-370. [More Information]
Gallagher, S., Mijatov, B., Gunatilake, D., Gowrishankar, K., Tiffen, J., James, W., Jin, L., Pupo, G., Cullinane, C., McArthur, G., Rizos, H., Hersey, P., et al (2014). Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151. Pigment Cell & Melanoma Research, 27(6), 1126-1137. [More Information]
Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
Wilmott, J., Haydu, L., Menzies, A., Lum, T., Hyman, J., Thompson, J., Hersey, P., Kefford, R., Scolyer, R., Long, G. (2014). Dynamics of chemokine, cytokine, and growth factor serum levels in BRAF-mutant melanoma patients during BRAF inhibitor treatment. Journal of Immunology, 192(5), 2505-2513. [More Information]
Hersey, P., Kakavand, H., Wilmott, J., van der Westhuizen, A., Gallagher, S., Gowrishankar, K., Scolyer, R. (2014). How Anti PD1 Treatments are Changing the Management Of Melanoma. Melanoma Management, 1(2), 165-172. [More Information]
Hersey, P., Gallagher, S. (2014). Intralesional immunotherapy for melanoma. Journal of Surgical Oncology, 109(4), 320-326. [More Information]
Oliveira, C., de Bock, C., Molloy, T., Sadeqzadeh, E., Geng, X., Hersey, P., Zhang, X., Thorne, R. (2014). Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma. BMC Cancer, 14, 1-14. [More Information]
Croft, A., Tay, K., Boyd, S., Guo, S., Jiang, C., Lai, F., Tseng, H., Jin, L., Rizos, H., Hersey, P., et al (2014). Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress. Journal of Investigative Dermatology, 134(2), 488-497. [More Information]
Coventry, B., Lilly, C., Hersey, P., Michele, A., Bright, R. (2014). Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma. Journal for ImmunoTherapy of Cancer, 2(1), 1-7. [More Information]
Jiang, C., Croft, A., Tseng, H., Guo, S., Jin, L., Hersey, P., Zhang, X. (2014). Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma. Oncogene, 33(20), 2577-2588. [More Information]
Gallagher, S., Mijatov, B., Gunatilake, D., Tiffen, J., Gowrishankar, K., Jin, L., Pupo, G., Cullinane, C., Prinjha, R., Smithers, N., Rizos, H., Hersey, P., et al (2014). The Epigenetic Regulator I-BET151 Induces BIM Dependent Apoptosis and Cell Cycle Arrest OF Human Melanoma Cells. Journal of Investigative Dermatology, 134(11), 2795-2805. [More Information]

show 8 more

2013

Hersey, P., Gallagher, S. (2013). A Focus on PD-L1 in Human Melanoma. Clinical Cancer Research, 19(3), 514-516. [More Information]
Mann, G., Pupo, G., Campain, A., Carter, C., Schramm, S., Pianova, S., Gerega, S., Desilva, C., Lai, K., Wilmott, J., Hersey, P., Kefford, R., Thompson, J., Yang, J., Scolyer, R., et al (2013). BRAF Mutation, NRAS Mutation, and the Absence of an Immune-Related Expressed Gene Profile Predict Poor Outcome in Patients with Stage III Melanoma. Journal of Investigative Dermatology, 133(2), 509-517. [More Information]
Lai, F., Guo, S., Jin, L., Jiang, C., Wang, C., Croft, A., Chi, M., Tseng, H., Farelly, M., Atmadibrata, B., Hersey, P., et al (2013). Cotargeting histone deactylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3. Cell Death and Disease, 4, 1-13. [More Information]
Wroblewski, D., Jiang, C., Croft, A., Farrelly, M., Zhang, X., Hersey, P. (2013). OBATOCLAX and ABT-737 induce ER stress responses in human melanoma cells that limit induction of apoptosis. PloS One, 8(12), 1-13. [More Information]
Hersey, P., Gallagher, S., Mijatov, B. (2013). Overcoming Resistance of Melanoma to Immunotherapy with Monoclonal Antibodies Against Checkpoints Inhibitors. In B. Bonavida (Eds.), Resistance to Immunotherapeutic Antibodies in Cancer: Resistance to Targeted Anti-Cancer Therapeutics, Vol 2, (pp. 143-155). United States: Springer Science+Business Media. [More Information]
Trunzer, K., Pavlick, A., Schuchter, L., Gonzalez, R., McArthur, G., Hutson, T., Moschos, S., Flaherty, K., Kim, K., Weber, J., Hersey, P., Long, G., et al (2013). Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma. Journal of Clinical Oncology, 31(14), 1767-1774. [More Information]
Ye, Y., Jin, L., Wilmott, J., Hu, W., Yosufi, B., Thorne, R., Liu, T., Rizos, H., Yan, X., Dong, L., Hersey, P., Scolyer, R., et al (2013). PI(4,5)P2 5-phosphatase A regulates PI3K/Akt signalling and has a tumour suppressive role in human melanoma. Nature Communications, 4, 1-15. [More Information]
Bowden, N., Ashton, K., Vilain, R., Avery-Kiejda, K., Davey, R., Murray, H., Budden, T., Braye, S., Zhang, X., Hersey, P., et al (2013). Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma. PloS One, 8(8), 1-8. [More Information]
Hamid, O., Robert, C., Daud, A., Hodi, F., Hwu, W., Kefford, R., Wolchok, J., Hersey, P., Joseph, R., Weber, J., et al (2013). Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. New England Journal of Medicine, 369(2), 134-144. [More Information]
Wroblewski, D., Mijatov, B., Mohana-Kumara, N., Lai, F., Gallagher, S., Haass, N., Zhang, X., Hersey, P. (2013). The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance. Carcinogenesis, 34(2), 237-247. [More Information]

show 7 more

2012

Wilmott, J., Scolyer, R., Long, G., Hersey, P. (2012). Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. OncoImmunology, 1(6), 997-999. [More Information]
Lai, F., Jiang, C., Farrelly, M., Zhang, X., Hersey, P. (2012). Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Melanoma Research, 22(3), 244-251. [More Information]
Lai, F., Jin, L., Gallagher, S., Mijatov, B., Zhang, X., Hersey, P. (2012). Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors. Advances in Pharmacology, 65, 27-43. [More Information]
Flaherty, K., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L., Hassel, J., Rutkowski, P., Mohr, P., et al (2012). Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. New England Journal of Medicine, 367(2), 107-114. [More Information]
Shayan, R., Karnezis, T., Murali, R., Wilmott, J., Ashton, M., Taylor, G., Thompson, J., Hersey, P., Achen, M., Scolyer, R., et al (2012). Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis. Histopathology, 61(4), 702-710. [More Information]
Lucas, K., Kumaran - Mohana, N., Lau, D., Zhang, X., Hersey, P., Huang, D., Weninger, W., Haass, N., Allen, J. (2012). Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737. Clinical Cancer Research, 18(3), 783-795. [More Information]
Ribas, A., Hersey, P., Middleton, M., Gogas, H., Flaherty, K., Sondak, V., Kirkwood, J. (2012). New challenges in endpoints for drug development in advanced melanoma. Clinical Cancer Research, 18(2), 336-341. [More Information]
Kirkwood, J., Bastholt, L., Robert, C., Sosman, J., Larkin, J., Hersey, P., Middleton, M., Cantarini, M., Zazulina, V., Kemsley, K., et al (2012). Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clinical Cancer Research, 18(2), 555-567. [More Information]
Wilmott, J., Long, G., Howle, J., Haydu, L., Sharma, R., Thompson, J., Kefford, R., Hersey, P., Scolyer, R. (2012). Selective BRAF inhibitors induce marked T - cell infiltration into human metastatic melanoma. Clinical Cancer Research, 18(5), 1386-1394. [More Information]
Tay, K., Jin, L., Tseng, H., Jiang, C., Ye, Y., Thorne, R., Liu, T., Guo, S., Verrills, N., Hersey, P., et al (2012). Suppression of PP2A is critical for protection of melanoma cells upon endoplasmic reticulum stress. Cell Death and Disease, 3, 1-11. [More Information]
Sosman, J., Kim, K., Schuchter, L., Gonzalez, R., Pavlick, A., Weber, J., McArthur, G., Hutson, T., Moschos, S., Flaherty, K., Hersey, P., Kefford, R., et al (2012). Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. New England Journal of Medicine, 366(8), 707-714. [More Information]
Hersey, P., Zhang, X. (2012). Targeting Apoptotic Pathways in Melanoma. In T F Gajewski, F S Hodi (Eds.), Targeted Therapeutics in Melanoma, (pp. 125-154). New York: Humana Press. [More Information]
Tseng, H., Chen, L., Ye, Y., Tay, K., Jiang, C., Guo, S., Jin, L., Hersey, P., Zhang, X. (2012). The melanoma-associated antigen MAGE-D2 suppresses TRAIL receptor 2 and protects against TRAIL-induced apoptosis in human melanoma cells. Carcinogenesis, 33(10), 1871-1881. [More Information]

show 10 more

2011

Zhang, X., Hersey, P., Tay, K., Tseng, H., Jiang, C., Dong, L. (2011). Adaptation to ER Stress as a Mechanism of Resistance of Melanoma to Treatment. In Ming Yu Cao (Eds.), Current Management of Malignant Melanoma, (pp. 253-274). Rijeka, Croatia: InTech Publishers. [More Information]
Sadeqzadeh, E., de Bock, C., Zhang, X., Shipman, K., Scott, N., Song, C., Yeadon, T., Oliveira, C., Jin, B., Hersey, P., et al (2011). Dual Processing of FAT1 Cadherin Protein by Human Melanoma Cells Generates Distinct Protein Products. Journal of Biological Chemistry, 286(32), 28181-28191. [More Information]
Dong, L., Jiang, C., Thorne, R., Croft, A., Yang, F., Liu, H., de Bock, C., Hersey, P., Zhang, X. (2011). Ets-1 mediates upregulation of Mcl-1 downstream of XBP-1 in human melanoma cells upon ER stress. Oncogene, 30(34), 3716-3726. [More Information]
Hersey, P., Smalley, K., Weeraratna, A., Bosenberg, M., Zhang, X., Haass, N., Paton, E., Mann, G., Scolyer, R. (2011). Meeting report from the 7th International Melanoma Congress, Sydney, November, 2010. Pigment Cell & Melanoma Research, 24(1), e1-e15. [More Information]
Jiang, C., Lai, F., Thorne, R., Yang, F., Liu, H., Hersey, P., Zhang, X. (2011). MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clinical Cancer Research, 17(4), 721-730. [More Information]
Jin, L., Hu, W., Jiang, C., Wang, J., Han, C., Chu, P., Zhang, L., Thorne, R., Wilmott, J., Scolyer, R., Hersey, P., et al (2011). MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma. Proceedings of the National Academy of Sciences of the United States of America, 108(38), 15840-15845. [More Information]
Avery-Kiejda, K., Bowden, N., Croft, A., Scurr, L., Kairupan, C., Ashton, K., Talseth-Palmer, B., Rizos, H., Zhang, X., Scott, R., et al (2011). P53 in human melanoma fails to regulate target genes associated with apoptosis and the cell cycle and may contribute to proliferation. BMC Cancer, 11(203), 1-17. [More Information]
Wilmott, J., Zhang, X., Hersey, P., Scolyer, R. (2011). The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers. Pathology, 43(6), 657-671. [More Information]
Zalaudek, I., Whiteman, D., Rosendahl, C., Menzies, S., Green, A., Hersey, P., Argenziano, G. (2011). Update on melanoma and non-melanoma skin cancer. Expert Review of Anticancer Therapy, 11(12), 1829-1832. [More Information]

show 6 more

2010

Hersey, P., Sosman, J., O'Day, S., Richards, J., Bedikian, A., Gonzalez, R., Sharfman, W., Weber, R., Logan, T., Buzoianu, M., et al (2010). A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma. Cancer, 116(6), 1526-1534. [More Information]
Kefford, R., Clingan, P., Brady, B., Ballmer, A., Morganti, A., Hersey, P. (2010). A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy. Molecular Cancer, 9(69), 69-1-69-9. [More Information]
Jiang, C., Lai, F., Tay, K., Croft, A., Rizos, H., Becker, T., Yang, F., Liu, H., Thorne, R., Hersey, P., et al (2010). Apoptosis of Human Melanoma Cells Induced by Inhibition of B-RAFV600E Involves Preferential Splicing of BimS. Cell Death and Disease, 1(9), e69-1-e69-14. [More Information]
Fonsatti, E., Maio, M., Altomonte, M., Hersey, P. (2010). Biology and clinical applications of CD40 in cancer treatment. Seminars in Oncology, 37(5), 517-523. [More Information]
Tseng, H., Jiang, C., Croft, A., Tay, K., Thorne, R., Yang, F., Liu, H., Hersey, P., Zhang, X. (2010). Contrasting Effects of Nutlin-3 on TRAIL- and Docetaxel-Induced Apoptosis Due to Upregulation of TRAIL-R2 and Mcl-1 in Human Melanoma Cells. Molecular Cancer Therapeutics, 9(12), 3363-3374. [More Information]
Yang, F., Tay, K., Dong, L., Thorne, R., Jiang, C., Yang, E., Tseng, H., Liu, H., Christopherson, R., Hersey, P., et al (2010). Cystatin B inhibition of TRAIL-induced apoptosis is associated with the protection of FLIP(L) from degradation by the E3 ligase itch in human melanoma cells. Cell Death and Differentiation, 17(8), 1354-1367. [More Information]
Hersey, P. (2010). Immunotherapy of melanoma. Asia-Pacific Journal of Clinical Oncology, 6(Suppl 1), S2-S8. [More Information]
Zhuang, L., Scolyer, R., Murali, R., McCarthy, S., Zhang, X., Thompson, J., Hersey, P. (2010). Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Modern Pathology, 23(1), 45-53. [More Information]
Bowden, N., Ashton, K., Avery-Kiejda, K., Zhang, X., Hersey, P., Scott, R. (2010). Nucleotide excision repair gene expression after Cisplatin treatment in melanoma. Cancer Research, 70(20), 7918-7926. [More Information]
Kirkwood, J., Lorigan, P., Hersey, P., Hauschild, A., Robert, C., McDermott, D., Marshall, M., Gomez-Navarro, J., Liang, J., Bulanhagui, C. (2010). Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clinical Cancer Research, 16(3), 1042-0432. [More Information]
Eisen, T., Trefzer, U., Hamilton, A., Hersey, P., Millward, M., Knight, R., Jungnelius, J., Glaspy, J. (2010). Results of a Multicenter, Randomized, Double-Blind Phase 2/3 Study of Lenalidomide in the Treatment of Pretreated Relapsed or Refractory Metastatic Malignant Melanoma. Cancer, 116(1), 146-154. [More Information]
Mao, Z., Jiang, C., Yang, F., Thorne, R., Hersey, P., Zhang, X. (2010). TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4. Apoptosis, 15(10), 1211-1222. [More Information]

show 9 more

2009

Liu, H., Jiang, C., Lavis, C., Croft, A., Dong, L., Tseng, H., Yang, F., Tay, K., Hersey, P., Zhang, X. (2009). 2-Deoxy-D-glucose enhances TRAIL-induced apoptosis in human melanoma cells through XBP-1-mediated up-regulation of TRAIL-R2. Molecular Cancer, 8, 1-17. [More Information]
Gogas, H., Eggermont, A., Hauschild, A., Hersey, P., Mohr, P., Schadendorf, D., Spatz, A., Dummer, R. (2009). Biomarkers in melanoma. Annals of Oncology, 20(SUPP 6), vi8-vi13. [More Information]
Zhuang, L., Scolyer, R., Lee, C., McCarthy, S., Cooper, W., Zhang, X., Thompson, J., Hersey, P. (2009). Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. Histopathology, 54(4), 462-470. [More Information]
Jiang, C., Mao, Z., Avery-Kiejda, K., Wade, M., Hersey, P., Zhang, X. (2009). Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells. Carcinogenesis, 30(2), 197-204. [More Information]
Jiang, C., Yang, F., Thorne, R., Zhu, B., Hersey, P., Zhang, X. (2009). Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. NeoPlasia: an international journal of oncology research, 11(5), 436-447. [More Information]
Jiang, C., Wroblewski, D., Yang, F., Hersey, P., Zhang, X. (2009). Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax. NeoPlasia: an international journal of oncology research, 11(9), 945-955. [More Information]
Schadendorf, D., Algarra, S., Bastholt, L., Cinat, G., Dreno, B., Eggermont, A., Espinosa, E., Guo, J., Hauschild, A., Petrella, T., Hersey, P., et al (2009). Immunotherapy of distant metastatic disease. Annals of Oncology, 20(6), vi41-vi50. [More Information]
Zhang, L., Chen, S., Wu, P., Hu, C., Thorne, R., Luo, C., Hersey, P., Zhang, X. (2009). Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells. Cancer Letters, 274(1), 40-46. [More Information]
Hersey, P., Watts, R., Zhang, X., Hackett, J. (2009). Metabolic approaches to treatment of melanoma. Clinical Cancer Research, 15(21), 6490-6494. [More Information]
Johnstone, D., Gomez Ravetti, M., Moscato, P., Hersey, P., Scott, R., Milward, E. (2009). Metabolic gene expression in advanced melanoma. ASMR NSW State Scientific Meeting, Sydney, NSW, Australia.
Watson, A., Middleton, M., McGown, G., Thorncraft, M., Ranson, M., Hersey, P., McArthur, G., Davis, I., Thomson, D., Beith, J., Kefford, R., et al (2009). O6-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. British Journal of Cancer, 100(8), 1250-1256. [More Information]
Hauschild, A., Agarwala, S., Trefzer, U., Hogg, D., Robert, C., Hersey, P., Eggermont, A., Grabbe, S., Gonzalez, R., Gille, J., et al (2009). Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. Journal of Clinical Oncology, 27(17), 2823-2830. [More Information]
Hersey, P., Bastholt, L., Chiarion-Sileni, V., Cinat, G., Dummer, R., Eggermont, A., Espinosa, E., Hauschild, A., Quirt, I., Robert, C., et al (2009). Small molecules and targeted therapies in distant metastatic disease. Annals of Oncology, 20(6), vi35-40. [More Information]
Beusterien, K., Szabo, S., Kotapati, S., Mukherjee, J., Hoos, A., Hersey, P., Middleton, M., Levy, A. (2009). Societal preference values for advanced melanoma health states in the United Kingdom and Australia. British Journal of Cancer, 101(3), 387-389. [More Information]
Milward, E., Johnstone, D., Gomez Ravetti, M., Berretta, R., Hersey, P., Scott, R., Moscato, P. (2009). The relationship between Parkinson's disease and melanoma - insights from microarray analysis of genome-wide gene expression changes in melanoma. ASMR National Scientific Conference, Hobart, TAS, Australia.
Hersey, P., Zhang, X. (2009). Treatment combinations targeting apoptosis to improve immunotherapy of melanoma. Cancer Immunology, Immunotherapy, 58(11), 1749-1759. [More Information]
Eggermont, A., Testori, A., Marsden, J., Hersey, P., Quirt, I., Petrella, T., Gogas, H., MacKie, R., Hauschild, A. (2009). Utility of adjuvant systemic therapy in melanoma. Annals of Oncology, 20(SUPP 6), vi30-vi34. [More Information]

show 14 more

2008

Zhu, B., Wang, P., Zhang, X., Jiang, C., Chen, L., Avery-Kiejda, K., Watts, R., Hersey, P. (2008). Activation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells. Anti-Cancer Drugs, 19(2), 189-200. [More Information]
Hersey, P., Zhang, X. (2008). Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma. Pigment Cell & Melanoma Research, 21(3), 358-367. [More Information]
Thompson, J., Hersey, P., Wachter, E. (2008). Chemoablation of metastatic melanoma using intralesional Rose Bengal. Melanoma Research, 18, 405-411. [More Information]
Zhang, L., Hao, Y., Hu, C., Ye, Y., Xie, Q., Thorne, R., Hersey, P., Zhang, X. (2008). Inhibition of apoptosis facilitates necrosis induced by cisplatin in gastric cancer cells. Anti-Cancer Drugs, 19(2), 159-166. [More Information]
Chen, L., Jiang, C., Watts, R., Thorne, R., Avery-Kiejda, K., Zhang, X., Hersey, P. (2008). Inhibition of endoplasmic reticulum stress-induced apoptosis of melanoma cells by the ARC protein. Cancer Research, 68(3), 834-842. [More Information]
Mhaidat, N., Thorne, R., Zhang, X., Hersey, P. (2008). Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma. Apoptosis, 13(12), 1505-1512. [More Information]
Mhaidat, N., Thorne, R., de Bock, C., Zhang, X., Hersey, P. (2008). Melanoma cell sensitivity to Docetaxel-induced apoptosis is determined by class III beta-tubulin levels. FEBS Letters, 582(2), 267-272. [More Information]
Hersey, P., Zhang, X., Mhaidat, N. (2008). Overcoming resistance to apoptosis in cancer therapy. Advances in Experimental Medicine and Biology, 615, 105-126. [More Information]
Hersey, P., Halliday, G., Farrelly, M., DeSilva, C., Menzies, S., Lett, M. (2008). Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunology, Immunotherapy, 57(7), 1039-1051. [More Information]
Avery-Kiejda, K., Zhang, X., Adams, L., Scott, R., Vojtesek, B., Lane, D., Hersey, P. (2008). Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clinical Cancer Research, 14(6), 1659-1668. [More Information]
Jiang, C., Lucas, K., Avery-Kiejda, K., Wade, M., deBock, C., Thorne, R., Allen, J., Hersey, P., Zhang, X. (2008). Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress. Cancer Research, 68(16), 6708-6717. [More Information]

show 8 more

2007

Yu, F., Chen, C., Kiejda, K., Gillespie, S., Xu, D., Hersey, P. (2007). Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clinical Cancer Research, 13(16), 4934-4942. [More Information]
Mhaidat, N., Wang, Y., Kiejda, K., Zhang, X., Hersey, P. (2007). Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2. Molecular Cancer Therapeutics, 6(2), 752-761. [More Information]
Mhaidat, N., Zhang, X., Jaing, C., Hersey, P. (2007). Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clinical Cancer Research, 13(4), 1308-1314. [More Information]
Jiang, C., Chen, L., Gillespie, S., Wang, Y., Kiejda, K., Zhang, X., Hersey, P. (2007). Inhibition of MEK Sensitizes Human Melanoma Cells to Endoplasmic Reticulum Stress-Induced Apoptosis. Cancer Research, 67(20), 9750-9761. [More Information]
Zhuang, L., Lee, C., Scolyer, R., McCarthy, S., Hersey, P., Thompson, J., Zhang, X. (2007). Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma whereas Bcl-2, AP-2 and MITF levels decrease during progression of melanoma. Modern Pathology, 20(4), 416-426. [More Information]
Ranson, M., Hersey, P., Thompson, D., Beith, J., McArthur, G., Haydon, A., Davis, I., Kefford, R., Mortimer, P., Harris, P., et al (2007). Randomised trial of the combination of lomeguatrib and temozolomide and temozolomide alone in chemotherapy-naÃ¯ve patients with metastatic cutaneous melanoma. Journal of Clinical Oncology, 25(18), 2540-2545. [More Information]
Mhaidat, N., Thorne, R., Zhang, X., Hersey, P. (2007). Regulation of docetaxel-induced apoptosis of human melanoma cells by different isoforms of protein kinase C. Molecular Cancer Research, 5(10), 1073-1081. [More Information]
Mhaidat, N., Zhang, X., Allen, J., Avery-Kiejda, K., Scott, R., Hersey, P. (2007). Temozolomide induces senescence but not apoptosis in human melanoma cells. British Journal of Cancer, 97(9), 1225-1233. [More Information]
Chen, L., Jiang, C., Kiejda, K., Wang, Y., Thorne, R., Zhang, X., Hersey, P. (2007). Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis by up-regulation of TRAIL-R2 through the unfolded protein response. Carcinogenesis, 28(11), 2328-2336. [More Information]
Chen, C., Li, H., Gillespie, S., Kiejda, K., Mhaidat, N., Yu, F., Thorne, R., Xu, D., Hersey, P. (2007). Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Research, 67(12), 5880-5888. [More Information]

show 7 more

2006

Hersey, P. (2006). Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Current Opinion in Oncology, 18(2), 189-96. [More Information]
Bedikian, A., Millward, M., Pehamberger, H., Conry, R., Gore, M., Trefzer, U., Pavlick, A., DeConti, R., Hersh, E., Hersey, P., et al (2006). Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group. Journal of Clinical Oncology, 24(29), 4738-4745. [More Information]
Gillespie, S., Borrow, J., Zhang, X., Hersey, P. (2006). Bim plays a crucial role in synergistic induction of apoptosis by the histone deacetylase inhibitor SBHA and TRAIL in melanoma cells. Apoptosis, 11(12), 2251-2265. [More Information]
Zhang, X., Wu, J., Gillespie, S., Borrow, J., Hersey, P. (2006). Cross resistance of melanoma to trail-induced apoptosis and chemotherapy. Update on Cancer Therapeutics, 1(4), 435-441. [More Information]
Hersey, P., Zhuang, L., Zhang, X. (2006). Current Strategies in Overcoming Resistance of Cancer Cells to Apoptosis Melanoma as a Model. International Review of Cytology-a Survey of Cell Biology, 251, 131-158. [More Information]
Zhang, X., Wu, J., Gillespie, S., Borrow, J., Hersey, P. (2006). Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clinical Cancer Research, 12(4), 1355-1364. [More Information]
Hersey, P. (2006). Involvement of BH3-only proapoptotic proteins in mitochondrial-dependent Phenoxodiol-induced apoptosis of human melanoma cells. Anti-Cancer Drugs, 17(10), 1151-61. [More Information]
Zhuang, L., Lee, C., Scolyer, R., McCarthy, S., Zhang, X., Thompson, J., Screaton, G., Hersey, P. (2006). Progression in melanoma is associated with decreased expression of death receptors for tumor necrosis factor-related apoptosis-inducing ligand. Human Pathology, 37(10), 1286-1294. [More Information]

show 5 more

2005

Zhuang, L., Lee, C., Scolyer, R., McCarthy, S., Palmer, A., Zhang, X., Thompson, J., Bron, L., Hersey, P. (2005). Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. Journal of Clinical Pathology, 58(11), 1163-1169. [More Information]
Millward, M., Joshua, A., Kefford, R., Aamdal, S., Thomson, D., Hersey, P., Toner, G., Lynch, K. (2005). Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma. Investigational New Drugs, 23(3), 253-256. [More Information]
Hersey, P., Menzies, S., Coventry, B., Nguyen, T., Farrelly, M., Collins, S., Hirst, D., Johnson, H. (2005). Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma. Cancer Immunology, Immunotherapy, 54(3), 208-218. [More Information]
Wu, J., Zhang, X., Gillespie, S., Hersey, P. (2005). Selection for TRAIL resistance results in melanoma cells with high proliferative potential. FEBS Letters, 579(9), 1940-1944. [More Information]
Byrne, C., Thompson, J., Johnston, H., Hersey, P., Quinn, M., Hughes, M., McCarthy, W. (2005). Treatment of metastatic melanoma using electroporation therapy with bleomycin (electrochemotherapy). Melanoma Research, 15(1), 45-51. [More Information]
Gillespie, S., Zhang, X., Hersey, P. (2005). Variable expression of protein kinase C epsilon in human melanoma cells regulates sensitivity to TRAIL-induced apoptosis. Molecular Cancer Therapeutics, 4(4), 668-76. [More Information]

show 3 more

2004

Bron, L., Scolyer, R., Thompson, J., Hersey, P. (2004). Histological Expression Of Tumour Necrosis Factor-Related Apoptosis-Inducing Ligand (Trail) In Human Primary Melanoma. Pathology, 36(6), 561-565. [More Information]
Hersey, P., Menzies, S., Halliday, G., Nguyen, T., Farrelly, M., De Silva, C., Lett, M. (2004). Phase I/II Study Of Treatment With Dendritic Cell Vaccines In Patients With Disseminated Melanoma. Cancer Immunology, Immunotherapy, 53(2), 125-134. [More Information]
Ishri, R., Menzies, S., Hersey, P., Halliday, G. (2004). Rapid Downregulation Of Antigen Processing Enzymes In Ex Vivo Generated Human Monocyte Derived Dendritic Cells Occur Endogenously In Extended Cultures. Immunology and Cell Biology, 82(3), 239-246. [More Information]
Thompson, J., Shaw, H., Hersey, P., Scolyer, R. (2004). The History And Future Of Melanoma Staging. Journal of Surgical Oncology, 86(4), 224-235. [More Information]

show 1 more

2002

Hanrahan, P., D'Este, C., Menzies, S., Plummer, T., Hersey, P. (2002). A randomised trial of skin photography as an aid to screening skin lesions in older males. Journal of Medical Screening, 9(3), 128-132. [More Information]
Coates, A., Thompson, J., McMullen, A., Simes, R., McCarthy, W., Hersey, P., Sillar, R., Mcleod, R., Gill, P., Coventry, B., Dhillon, H. (2002). Adjuvant Immunotherapy of Patients with High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial. Journal of Clinical Oncology, 20(20), 4181-4189.

2001

Saleh, F., Crotty, K., Menzies, S., Hersey, P. (2001). Primary melanoma tumour regression associated with an immune response to the tumour-associated antigen melan-a/mart-1. International Journal of Cancer, 94, 551-557. [More Information]

Selected Grants

2022

Testing Nicotinamide as a metabolic adjuvant to increase efficacy of immunotherapy in melanoma, Alavi S, Shklovskaya E, Hersey P, Australian Melanoma Research Foundation/Research Grants

2021

Unleashing the Immune Response Against Melanoma by Targeting a Critical Epigenetic Axis, Tiffen J, Hersey P, Gallagher S, Cancer Council NSW/Project Grant

2018

Epigenetic targeting of T cell dysfunction "exhaustion" in patients failing treatment with immune checkpoint inhibitors, Hersey P, McGuire H, Shklovskaya E, Gallagher S, Carlino M, Cancer Council NSW/Research Grant

2017

The Sydney University Immunotherapy Hub: Improving the efficacy of Immunotherapy, Palendira M, Britton W, Scolyer R, Long G, O'Toole S, Hersey P, DVC Research/Sydney Research Excellence Initiative 2020 (SREI)

2015

Molecular determinants of risk, progression and treatment response in melanoma, Kefford R, Thompson J, Hersey P, Mann G, Scolyer R, Hayward N, Long G, National Health and Medical Research Council (NHMRC)/Program Grants

2014

Qseq automated personal DNA sequencer, Pollock C, Marsh D, Hersey P, Howell V, Sue C, DVC Research/Equipment Grant
Overcoming Resistance of Human Melanoma to Systemic Treatments, Hersey P, University of Sydney/Internal Scheme

2013

BioMark HD High-throughput Real Time & Digital PCR System for the Open Access, Multi-Disciplinary Sydney Cancer Research Core Facility, Richardson D, Scolyer R, Lee C, Halliday G, Murray M, Lay P, Christie M, Kench J, Damian D, Hersey P, Cancer Institute NSW/Equipment Grant

2010

Molecular determinants of risk, progression and treatment response in melanoma, Hayward N, Hersey P, Kefford R, Kefford R, Thompson J, Hersey P, Mann G, Scolyer R, National Health and Medical Research Council (NHMRC)/Program Grants

2005

Sydney Melanoma Unit Translational Research Program, Mann G, Thompson J, Kefford R, Scolyer R, Menzies S, Hersey P, Christopherson R, Cancer Institute NSW/Translational Research Program Grant

1999

Immunotherapy of melanoma with dendritic cells, Hersey P, Halliday G, Menzies S, National Health and Medical Research Council (NHMRC)/Project Grants

Page not found

Professor Peter Hersey

Publications

By Type

By Year

Selected Grants

2022

2021

2018

2017

2015

2014

2013

2010

2005

1999